- Home
- AAC vs ALLO Comparison
AAC vs ALLO Comparison
Compare AAC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAC | ALLO |
|---|---|---|
| Founded | 2026 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.1M | 483.7M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AAC | ALLO |
|---|---|---|
| Price | $10.00 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 64.2K | ★ 5.5M |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $255.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.95 | $1.04 |
| 52 Week High | $10.15 | $4.46 |
Technical Indicators
Market Signals| Indicator | AAC | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 27.24 |
| Support Level | $9.95 | N/A |
| Resistance Level | $10.07 | $2.22 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 25.00 | 24.72 |
Price Performance
Historical ComparisonAbout AAC Ares Acquisition Corporation III Class A Ordinary Shares
Ares Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).